{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(4)"],"submitter":["Sekai I"],"pubmed_abstract":["Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after en"],"journal":["Clinical journal of gastroenterology"],"pagination":["1191-1196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8298218"],"repository":["biostudies-literature"],"pubmed_title":["A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells."],"pmcid":["PMC8298218"],"pubmed_authors":["Watanabe T","Kudo M","Sekai I","Hagiwara S"],"additional_accession":[]},"is_claimable":false,"name":"A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells.","description":"Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after en","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-04T09:30:29.852Z","creation":"2022-02-10T21:48:57.22Z"},"accession":"S-EPMC8298218","cross_references":{"pubmed":["33665689"],"doi":["10.1007/s12328-020-01317-y"]}}